 GenMark Diagnostics, Inc. GNMK, a leading provider of automated, multiplex molecular diagnostic testing systems, announced that its ePlex Respiratory Pathogen 2 RP2 Panel is now available for U.S. commercial distribution and clinical use. The ePlex RP2 Panel is one of the first rapid-result multiplex panel tests that can identify 21 pathogens, including SARS-CoV-2, to be made available for clinical use. The company also submitted an Emergency Use Authorization EUA to the U.S. Food and Drug Administration for the ePlex Respiratory Pathogen 2 RP2 Panel earlier this month. 